Restoring mucosal barrier function
Synedgen's first-in-class therapeutics improve patient outcomes by promoting barrier function to repair mucosal injury
Learn about our technologyProtecting the gastrointestinal (GI) tract from injury
Synedgen’s current lead asset is MIIST305, a clinic-ready, orally delivered therapeutic that repairs GI mucosal injury. MIIST305 restores GI function and reduces unchecked inflammation and damage.
Learn about MIIST305First-In-Class Therapies to Protect, Restore, and Repair the Body

Targeted therapies

Scalable GMP production

Excellent safety profiles

Strong IP Position
Our Regenerative Therapeutics
Synedgen's therapeutics have demonstrated efficacy across multiple modalities
See our full portfolioNews
October 19, 2021
SWM International’s Scapa Healthcare Business Signs Exclusive Technology Licensing Agreement for Novel Wound Care Technology with Synedgen, Inc.
Read More
August 5, 2021
Synedgen Initiates Clinical Trial Assessing Combination of SynePure and Catasyn for the Treatment of Partial Thickness Burns
Read More
February 18, 2021
Synedgen Appoints Industry Veteran Dennis Fenton, Ph.D., to Board of Directors
Read More